Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
RNA Interference01:23

RNA Interference

25.7K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.7K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Replenishing Hope: The Time for Country-Led Integration Is Now.

International journal of health policy and management·2026
Same author

RNA editing for the treatment of alpha-1 antitrypsin deficiency.

Nucleic acids research·2026
Same author

Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy.

Frontiers in immunology·2024
Same author

Incidence of bacterial blood stream infections in patients with acute GVHD.

Bone marrow transplantation·2024
Same author

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer.

Cancer immunology, immunotherapy : CII·2024
Same author

Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing.

Nucleic acids research·2024
Same journal

Network Pharmacology and Animal Experimental Validation on the Therapeutic Mechanisms of <i>Prunus cerasifera</i> Extract in Psoriasis.

Clinical, cosmetic and investigational dermatology·2026
Same journal

Evaluation of Parameters Determining the Pull-Out Strength of Poly(L-Lactide-Co-ε-Caprolactone) Barbed Suspension Threads: A Comparative ex vivo Study.

Clinical, cosmetic and investigational dermatology·2026
Same journal

Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission.

Clinical, cosmetic and investigational dermatology·2026
Same journal

Evolving Research Hotspots and Emerging Trends in Atopic Dermatitis and Inflammatory Bowel Disease: A Bibliometric Analysis.

Clinical, cosmetic and investigational dermatology·2026
Same journal

A Preliminary Study of Polycaprolactone Filler After Hyaluronidase for Facial Overfilled Syndrome.

Clinical, cosmetic and investigational dermatology·2026
Same journal

Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib.

Clinical, cosmetic and investigational dermatology·2026
See all related articles

Related Experiment Video

Updated: May 7, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K

Self-Delivering RNAi Compounds for Reduction of Hyperpigmentation.

Melissa Maxwell1, Katherine Holton1, Richard J Looby1

  • 1Phio Pharmaceuticals, Marlborough, MA, USA.

Clinical, Cosmetic and Investigational Dermatology
|January 1, 2025
PubMed
Summary
This summary is machine-generated.

INTASYL compounds, like RXI-231, effectively reduce melanin synthesis by targeting tyrosinase gene expression. This RNA interference approach shows promise for treating hyperpigmentation disorders with a non-irritant profile.

Keywords:
RNA interference (RNAi)epidermal culture modelshyperpigmentationmelanin biosynthesistyrosinase inhibitors

More Related Videos

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.6K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Experiment Videos

Last Updated: May 7, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.6K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Area of Science:

  • Dermatology and Molecular Biology
  • RNA interference (RNAi) therapeutics
  • Melanogenesis and Hyperpigmentation Research

Background:

  • Hyperpigmentation disorders, such as melasma and lentigines, result from abnormal melanin synthesis and can negatively impact psychological well-being.
  • RNA interference (RNAi) is a biological process utilizing small RNA molecules to inhibit gene expression by targeting specific messenger RNA (mRNA).
  • INTASYL compounds are novel self-delivering RNAi molecules engineered to target and reduce gene expression involved in undesirable cellular functions, including pigmentation.

Purpose of the Study:

  • To assess the efficacy of INTASYL compounds in reducing tyrosinase gene expression, a key enzyme in melanin synthesis.
  • To evaluate the lead compound, RXI-231, for its ability to decrease pigmentation in vitro and in a 3D human skin model.
  • To determine the safety and skin penetration profile of INTASYL compounds.

Main Methods:

  • 36 INTASYL compounds were designed to target the TYR gene, with lead compound RXI-231 further tested in normal human melanocytes and the MelanoDerm™ model.
  • RXI-231's efficacy was assessed by measuring tyrosinase mRNA levels, in vitro dopachrome formation, and melanin content.
  • Skin penetration and irritation potential were evaluated using porcine skin explants and the MatTek EpiDerm™ model, respectively.

Main Results:

  • RXI-231 significantly reduced tyrosinase mRNA expression, dopachrome formation, and melanin content in both normal human melanocytes and the MelanoDerm model.
  • Visible reduction in pigmentation was observed in 3D epidermal cultures with regular application of INTASYL compounds.
  • Penetration studies confirmed efficient delivery into the epidermis, and RXI-231 demonstrated a non-irritant profile in the EpiDerm™ model.

Conclusions:

  • RXI-231 effectively inhibits tyrosinase activity and melanin synthesis, presenting a promising therapeutic candidate for hyperpigmentation disorders.
  • The compound's ability to penetrate the skin and its non-irritant nature support its potential for topical application.
  • Further clinical studies are warranted to confirm the therapeutic efficacy and safety of RXI-231 in human patients.